Heart Failure Drugs Market Global Trends, Size, Segments and Growth by Forecast to 2030
Heart
Failure Drugs Market Overview
People more than 60 years of age are the major patient pool in the global market. The demographic is marked by reduced immunity levels and are therefore vulnerable to chronic ailments including heart failure. Therefore, the consistent expansion of the geriatric population worldwide will be a significant growth booster in the Heart Failure Drugs Market over the ensuing years.
The Centers for Disease Control and
Prevention reveals that nearly 5.7 million people in the US suffer from heart
failure. The condition is marked by the heart’s inability to pump sufficient
blood as well as oxygen that are required for supporting all the other organs
in the human body. It is a serious disorder, although the heart continues to
beat. But past reports show that more than half of the patients that developed
heart failure die within 6 years of being diagnosed.
Heart failure has emerged as one of
the most lethal health conditions in the world and affects patients that lead
unhealthy lifestyle and face poor prognosis. Risk factors are hypertension,
obesity and diabetes, all of which have been witnessing a surge in the global
current population. Unmet medical needs are quite high, especially in emerging
regions, and the demand for reduced mortality should elevate the need for more
drugs in the global market. Growing number of approvals as well as launch of
the ACE inhibitors and the robustness of the latest pipeline can also enhance
the market share in the coming years.
Market Research Future (MRFR) believes that the heart failure drugs market can record a decent growth rate of 5.9% between 2022 and 2030 (appraisal period). It is also projected that the market size can touch USD 18.10 Billion by 2030.
Major Firms
Merck Sharp & Dohme Corp. (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Gilead Sciences, Inc. (California), Amgen Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Boehringer Ingelheim International GmbH (Germany), Pfizer, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.K.), are the prominent firms in the global market for heart failure drugs market Players
Heart Failure Drugs Market Segmentation
The key segments highlighted in the
MRFR study of the Heart Failure Drugs industry include type and end-user.
The global market, depending on type,
caters to ACE Inhibitors, Diuretic, Beta-Blockers, Angiotensin Receptor
Blockers (ARBs), Angiotensin-Receptor Neprilysin Inhibitors (ARNI), and others.
ACE inhibitors are the most extensively prescribed types of drugs, as these
play an essential role in managing heart failure. These relax the blood vessels
and bring down the blood pressure, thereby facilitating smooth blood flow.
The global heart failure drugs market,
by end-user, has been categorized as hospitals, specialty centers, and others.
Hospital segment has procured the leading position in the global industry, on
account of their soaring number worldwide and medications increasingly being
prescribed at these institutions.
Heart
Failure Drugs Market Regional Analysis
The market for heart failure drugs has
been regionally segregated into Asia Pacific/APAC, Americas, MEA or Middle East
& Africa and Europe.
Americas has taken the prime spot in
the global market since the region generates significant demand for heart
failure drugs in view of the escalating cases of cardiovascular disorder. High
healthcare spending along with the surge in obesity cases also add to the
market value. Besides, the growing prevalence of unhealthy lifestyle including
high alcohol intake, bad diet, smoking, and lack of exercise has raised people’s
vulnerability to arrhythmia as well as heart failure. This is bound to create a
favorable scenario for the regional market in the following years.
Europe is the second most lucrative
market for heart failure drugs and will continue to record a considerable
growth rate in the ensuing years. The soaring incidences of cardiovascular
diseases along with the burgeoning population of smokers has amplified the
market growth rate in the region. Moreover, the expanding elderly populace in
the European Union should also benefit the regional market over the analysis
period.
Asia Pacific is emerging as one of the strongest markets, thanks to the blossoming patient pool along with the surge in technological advances in healthcare. The market’s rapid growth is also the result of the rise in per capita income as well as government initiatives aimed at improving the healthcare infrastructure.
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting
Services. MRFR team have supreme objective to provide the optimum quality
market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research
and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
.jpg)
Comments
Post a Comment